Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Taro Pharm Inds (NY: TARO )

42.69 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 42.69
Bid (Size) 41.50 (1)
Ask (Size) 45.00 (1)
Prev. Close 42.69
Today's Range 42.69 - 42.69
52wk Range 28.10 - 45.76
Shares Outstanding 37,584,631
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TARO Stock Earnings: Taro Pharmaceutical Indus Reported Results for Q4 2024
Taro Pharmaceutical Indus just reported results for the fourth quarter of 2024. 
Via InvestorPlace
Taro Provides Results for Year Ended March 31, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire

Performance

YTD
+2.23%
+2.23%
1 Month
+1.16%
+1.16%
3 Month
+1.50%
+1.50%
6 Month
+16.86%
+16.86%
1 Year
+47.36%
+47.36%

More News

Read More
Taro to Release Full Year Results on May 20, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
From Kahn Swick & Foti, LLC
Via Business Wire
Earnings Preview For Taro Pharmaceutical Indus
Via Benzinga
Taro Pharmaceutical Indus Earnings Preview
Via Benzinga
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rover Group, Inc. (Nasdaq - ROVR), M.D.C. Holdings, Inc. (NYSE - MDC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE - PGTI)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Shares of Taro Pharmaceutical Are Rising Tuesday
Via The Motley Fool
Taro Provides Results for December 31, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rover Group, Inc. (Nasdaq - ROVR), M.D.C. Holdings, Inc. (NYSE - MDC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE - PGTI)
From Brodsky & Smith LLC
Via GlobeNewswire
Taro to Release Third Quarter Results on January 25, 2024
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Earnings Scheduled For January 25, 2024
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: M.D.C. Holdings, Inc. (NYSE - MDC), Cornerstone Financial Corporation (OTC - CFIC), Taro Pharmaceutical Industries Ltd. (NYSE - TARO), PGT Innovations Inc. (NYSE -
From Brodsky & Smith LLC
Via GlobeNewswire
TARO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Taro Pharmaceutical Industries Ltd. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Taro Provides Results for September 30, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Earnings Scheduled For October 26, 2023
Via Benzinga
Taro to Release Second Quarter Results on October 26, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro Provides Results for the Quarter Ended June 30, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro to Release First Quarter Results on July 26, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023
From Taro Pharmaceutical Industries Ltd.
Via Business Wire
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) Near the Top of Equities by Percentage Gain on 5/30
Via Investor Brand Network
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.